{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:07:35Z","timestamp":1760148455991,"version":"build-2065373602"},"reference-count":133,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma.<\/jats:p>","DOI":"10.3390\/cancers15092633","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T02:03:31Z","timestamp":1683511411000},"page":"2633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adoptive Immunotherapy and High-Risk Myeloma"],"prefix":"10.3390","volume":"15","author":[{"given":"Catherine","family":"Duane","sequence":"first","affiliation":[{"name":"Department of Haematology, Beaumont Hospital, D09 V2N0 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Galway, H91 TK33 Galway, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"Glavey","sequence":"additional","affiliation":[{"name":"Department of Haematology, Beaumont Hospital, D09 V2N0 Dublin, Ireland"},{"name":"Department of Pathology, Royal College of Surgeons in Ireland, D09 V2N0 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from In-ternational Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.550","article-title":"Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma","volume":"101","author":"Laubach","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1096852","DOI":"10.3389\/fonc.2022.1096852","article-title":"Experts\u2019 consensus on the definition and management of high risk multiple myeloma","volume":"12","author":"Marcon","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: Heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2015.209","article-title":"Defining and treating high-risk multiple myeloma","volume":"29","author":"Usmani","year":"2015","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","first-page":"1008","article-title":"Gene expression profiling as a prognostic tool in multiple myeloma","volume":"4","author":"Black","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sanoja-Flores, L., Flores-Montero, J., P\u00e9rez-Andr\u00e9s, M., Puig, N., and Orfao, A. (2020). Detection of circulating tumor plasma cells in monoclonal gammo-pathies: Methods, pathogenic role, and clinical implications. Cancers, 12.","DOI":"10.3390\/cancers12061499"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136553","article-title":"Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients","volume":"136","author":"Soekojo","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Beksac","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated My-eloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With \u22653 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","article-title":"Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma","volume":"36","author":"Zanwar","year":"2022","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to Treat High-Risk Myeloma at Diagnosis and Relapse","volume":"41","author":"Caro","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2022-159540","article-title":"Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalido-mide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum\/Muknine Trial","volume":"140","author":"Kaiser","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"F\u00fcchsl, F., and Krackhardt, A.M. (2022). Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. Cells, 11.","DOI":"10.3390\/cells11030410"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: The Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malign- Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-cell receptor-based therapy: An innovative therapeutic approach for solid tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2015.12.001","article-title":"Chimeric antigen receptor-redirected T cells return to the bench","volume":"28","author":"Geldres","year":"2016","journal-title":"Semin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: Structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with re-lapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"755866","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients with Ex-tramedullary Disease: A Single Center Analysis of Two Clinical Trials","volume":"12","author":"Que","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gagelmann, N., Ayuk, F.A., Klyuchnikov, E., Wolschke, C., Berger, S.C., and Kr\u00f6ger, N. (2023). Impact of high-risk disease on efficacy of CAR-T cell therapy for multiple my-eloma: A meta-analysis of 723 patients. Haematologica.","DOI":"10.3324\/haematol.2022.282510"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139009","article-title":"KarMMa-4, Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma","volume":"136","author":"Usmani","year":"2020","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2020-137786","article-title":"Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1\/2 Evolve Study (NCT03430011)","volume":"136","author":"Piasecki","year":"2020","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Re-ceptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13256-020-02598-0","article-title":"Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: A case report","volume":"15","author":"Madduri","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1182\/blood-2022-159169","article-title":"Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up","volume":"140","author":"Agha","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Expe-rience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","article-title":"Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma","volume":"8","author":"Pilcher","year":"2023","journal-title":"NPJ Genom. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: From biology to clinical practice","volume":"108","author":"Zhou","year":"2022","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood-2022-167602","article-title":"Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape\u2013Driven Relapse in Multiple Myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple my-eloma","volume":"41","author":"Tang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"Ritchey","year":"2022","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2022-162295","article-title":"Phase I Open-Label Single-Arm Study of BCMA\/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma","volume":"140","author":"Du","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2022.2030476","article-title":"A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cy-totoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fonc.2020.568056","article-title":"Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation with Implications for Adoptive T-Cell Therapy","volume":"10","author":"Mika","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Desantis, V., Savino, F.D., Scaringella, A., Potenza, M.A., Nacci, C., Frassanito, M.A., Vacca, A., and Montagnani, M. (2022). The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092513"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"100473","DOI":"10.1016\/j.ctarc.2021.100473","article-title":"Oncolytic virotherapy\u2014Forging its place in the immunomodulatory paradigm for Multiple Myeloma","volume":"29","author":"Cook","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e20192203","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 co-expression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2018025106","article-title":"p53 regulates CD46 expression and measles virus infection in myeloma cells","volume":"2","author":"Lok","year":"2018","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.HS9.0000846604.67185.0c","article-title":"P934, Daratumumab + Lenalidomide, Bortezomib and Dexamethasone in Transplant Eligibly Newly Diagnosed Multiple Myeloma: A Post Hoc Analysis of Sustained Minimal Residual Disease Negativity from GRIFFIN","volume":"6","author":"Rodriguez","year":"2022","journal-title":"HemaSphere"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.2020008090","article-title":"Undetectable MRD can change the deal","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2018.36.15_suppl.8006","article-title":"Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma","volume":"36","author":"Shah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","article-title":"Highly activated and expanded natural killer cells for multiple myeloma immunotherapy","volume":"97","author":"Garg","year":"2012","journal-title":"Haematologica"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13287-021-02251-7","article-title":"Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/HS9.0000000000000596","article-title":"CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an \u201cOff the Shelf\u201d Therapy for Multiple Myeloma","volume":"5","author":"Stikvoort","year":"2021","journal-title":"Hemasphere"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","article-title":"Novel immunotherapies in multiple myeloma","volume":"115","author":"Ohmine","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained anti-gen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"Szmania","year":"2005","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"TPS3101","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3101","article-title":"Autologous genetically engineered NY-ESO-1c259T in HLA-A*02, 01, HLA*02, 05 and HLA*02, 06 positive patients with NY-ESO-1 expressing tumors","volume":"34","author":"Mackall","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.2700","article-title":"Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","article-title":"Orthotopic replacement of T-cell receptor \u03b1- and \u03b2-chains with preservation of near-physiological T-cell function","volume":"3","author":"Schober","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of Programmed Death 1 Augments the Ability of Human T Cells En-gineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:30:14Z","timestamp":1760124614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/9\/2633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":133,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15092633"],"URL":"https:\/\/doi.org\/10.3390\/cancers15092633","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,5,6]]}}}